NASA Logo

NTRS

NTRS - NASA Technical Reports Server

Back to Results
Space Motion Sickness - Analysis of Medical Debriefs Data for Incidence and TreatmentAstronauts use medications for the treatment of a variety of illnesses during space travel. Data mining efforts to assess minor clinical conditions occurring during Shuttle flights STS-1 through STS-94 revealed that space motion sickness (SMS) was the most common ailment during early flight days, occurring in approx.40% of crewmembers, followed by digestive system disturbances (9%) and infectious diseases, which most commonly involved the respiratory or urinary tracts. A more recent analysis of postflight medical debriefs data to examine trends with respect to medication use by astronauts during spaceflights indicated that ~37% of all prescriptions recorded was for pain followed by sleep (22%), SMS (18%), decongestion (14%), and all others (14%). Further analysis revealed that about 150 of 317 crewmembers experienced symptoms of SMS. Nearly all (132 of 150) crewmembers took medication for the treatment of symptoms with a total of 387 doses. Promethazine was taken most often (201 doses); in most cases this resulted in alleviation of symptoms with 130 crewmembers (65%) reporting feeling much or somewhat better. Although fewer total doses of the combination of promethazine and dextroamphetamine (Phen/Dex) were taken (45 doses), slightly more than half of these doses resulted in improvement. The combination of scopolamine and dextroamphetamine (Scop/Dex) was reported to be effective in only 37% of cases, with 36 of 97 total doses resulting in improvement. A higher percentage (24%) of Scop/Dex doses was reported to be ineffective compared with promethazine alone or as Phen/Dex (10% and 7%, respectively). Comparisons of the effectiveness of the different dosage forms of promethazine revealed that intramuscular injection was most effective in alleviating symptoms with 55% feeling much better, 16% feeling somewhat better, and only 7% feeling no effect or worse. Overall, it appears that promethazine alone was used more frequently during flight and was reported effective for the treatment of SMS.
Document ID
20110020471
Acquisition Source
Johnson Space Center
Document Type
Abstract
Authors
Putcha, Lakshmi
(NASA Johnson Space Center Houston, TX, United States)
Younker, D.
(Wyle Integrated Science and Engineering Group Houston, TX, United States)
Daniels, V.
(Wyle Integrated Science and Engineering Group Houston, TX, United States)
Date Acquired
August 25, 2013
Publication Date
January 2, 2011
Subject Category
Aerospace Medicine
Report/Patent Number
JSC-CN-25040
Report Number: JSC-CN-25040
Meeting Information
Meeting: 83rd AsMA Annual Scientific Meeting
Location: Atlanta, GA
Country: United States
Start Date: May 13, 2012
End Date: May 17, 2012
Sponsors: Aerospace Medical Association
Distribution Limits
Public
Copyright
Public Use Permitted.
No Preview Available